Business Description
PT Merck Tbk
ISIN : ID1000136609
Compare
Compare
Traded in other countries / regions
MERK.IndonesiaPMKIF.USA IPO Date
1981-07-23Description
PT Merck Tbk engages in the manufacture and sale of pharmaceutical products in Indonesia. The company operates in three segments: Biopharma, Consumer Health, and Others. The company offers pharmaceutical and biological prescription medicines for colorectal cancer, head and neck tumors, multiple sclerosis, infertility, growth hormone disorders, cardiovascular disorders, diabetes, as well as thyroid disorders such as hypothyroidism.
Financial Strength
9/10
| Name | Current | Vs Industry | Vs History | |||
|---|---|---|---|---|---|---|
| Cash-To-Debt | 4.16 | |||||
| Equity-to-Asset | 0.8 | |||||
| Debt-to-Equity | 0.03 | |||||
| Debt-to-EBITDA | 0.13 | |||||
| Interest Coverage | 30.72 | |||||
| Piotroski F-Score | 3/9 | |||||
| Altman Z-Score | 8.23 | |||||
| Beneish M-Score | -1.99 | |||||
| WACC vs ROIC | ||||||
Growth Rank
5/10
| Name | Current | Vs Industry | Vs History | |||
|---|---|---|---|---|---|---|
| 3-Year Revenue Growth Rate | 13.6 | |||||
| 3-Year EBITDA Growth Rate | 21.3 | |||||
| 3-Year EPS without NRI Growth Rate | 35.5 | |||||
| 3-Year FCF Growth Rate | 65.5 | |||||
| 3-Year Book Growth Rate | 9.1 |
Momentum Rank
2/10
| Name | Current | Vs Industry | Vs History | |||
|---|---|---|---|---|---|---|
| 5-Day RSI | 85.87 | |||||
| 9-Day RSI | 71.48 | |||||
| 14-Day RSI | 61.08 | |||||
| 3-1 Month Momentum % | -8.64 | |||||
| 6-1 Month Momentum % | -10.28 | |||||
| 12-1 Month Momentum % | -17.88 |
Liquidity Ratio
| Name | Current | Vs Industry | Vs History | |||
|---|---|---|---|---|---|---|
| Current Ratio | 4.53 | |||||
| Quick Ratio | 1.7 | |||||
| Cash Ratio | 0.52 | |||||
| Days Inventory | 235.27 | |||||
| Days Sales Outstanding | 58.16 | |||||
| Days Payable | 44.57 |
Dividend & Buy Back
| Name | Current | Vs Industry | Vs History | |||
|---|---|---|---|---|---|---|
| Dividend Yield % | 8.91 | |||||
| Dividend Payout Ratio | 1.15 | |||||
| 3-Year Dividend Growth Rate | 35 | |||||
| Forward Dividend Yield % | 8.91 | |||||
| 5-Year Yield-on-Cost % | 8.96 | |||||
| Shareholder Yield % | 9.06 |
Profitability Rank
9/10
| Name | Current | Vs Industry | Vs History | |||
|---|---|---|---|---|---|---|
| Gross Margin % | 34.9 | |||||
| Operating Margin % | 13.48 | |||||
| Net Margin % | 13.36 | |||||
| FCF Margin % | 7.42 | |||||
| ROE % | 16.48 | |||||
| ROA % | 12.91 | |||||
| ROIC % | 16.34 | |||||
| 3-Year ROIIC % | 483.59 | |||||
| ROC (Joel Greenblatt) % | 22.91 | |||||
| ROCE % | 17.35 | |||||
| Years of Profitability over Past 10-Year | 10 |
GF Value Rank
7/10
| Name | Current | Vs Industry | Vs History | |||
|---|---|---|---|---|---|---|
| PE Ratio | 12.92 | |||||
| PE Ratio without NRI | 12.92 | |||||
| Shiller PE Ratio | 3.9 | |||||
| Price-to-Owner-Earnings | 13.63 | |||||
| PEG Ratio | 0.41 | |||||
| PS Ratio | 1.72 | |||||
| PB Ratio | 2.2 | |||||
| Price-to-Tangible-Book | 2.21 | |||||
| Price-to-Free-Cash-Flow | 23.2 | |||||
| Price-to-Operating-Cash-Flow | 19.84 | |||||
| EV-to-EBIT | 11.19 | |||||
| EV-to-EBITDA | 10.51 | |||||
| EV-to-Revenue | 1.66 | |||||
| EV-to-FCF | 21.58 | |||||
| Price-to-GF-Value | 0.9 | |||||
| Price-to-Projected-FCF | 1.7 | |||||
| Price-to-Median-PS-Value | 0.78 | |||||
| Price-to-Peter-Lynch-Fair-Value | 0.64 | |||||
| Price-to-Graham-Number | 1.13 | |||||
| Price-to-Net-Current-Asset-Value | 3.33 | |||||
| Earnings Yield (Greenblatt) % | 8.93 | |||||
| FCF Yield % | 4.32 | |||||
| Forward Rate of Return (Yacktman) % | 26.63 |
Historical Operating Revenue by Business Segment
Historical Operating Revenue by Geographic Region
Guru Trades
See DetailsInsider Trades
See DetailsPeter Lynch Chart
Performance
Dividend
Log
Bar
Annualized Return % Â
Total Annual Return % Â
PT Merck Tbk Executives
DetailsAnalyst Estimate
Key Statistics
| Name | Value | ||
|---|---|---|---|
| Revenue (TTM) (Mil Rp) | 934,620.903 | ||
| EPS (TTM) (Rp) | 277.807 | ||
| Beta | 0.49 | ||
| 3-Year Sharpe Ratio | -0.19 | ||
| 3-Year Sortino Ratio | -0.32 | ||
| Volatility % | 12.07 | ||
| 14-Day RSI | 61.08 | ||
| 14-Day ATR (Rp) | 75.609023 | ||
| 20-Day SMA (Rp) | 3474 | ||
| 12-1 Month Momentum % | -17.88 | ||
| 52-Week Range (Rp) | 3390 - 4400 | ||
| Shares Outstanding (Mil) | 448 |
Piotroski F-Score Details
Year:
| Component | Result | ||
|---|---|---|---|
| Piotroski F-Score | 3 | ||
| Positive ROA | |||
| Positive CFROA | |||
| Higher ROA yoy | |||
| CFROA > ROA | |||
| Lower Leverage yoy | |||
| Higher Current Ratio yoy | |||
| Less Shares Outstanding yoy | |||
| Higher Gross Margin yoy | |||
| Higher Asset Turnover yoy |
PT Merck Tbk Filings
| Filing Date | Document Date | Form | ||
|---|---|---|---|---|
| No Filing Data | ||||
PT Merck Tbk Stock Events
| Event | Date | Price (Rp) | ||
|---|---|---|---|---|
| No Event Data | ||||
PT Merck Tbk Frequently Asked Questions
What is PT Merck Tbk(ISX:MERK)'s stock price today?
The current price of ISX:MERK is Rp3590.00. The 52 week high of ISX:MERK is Rp4400.00 and 52 week low is Rp3390.00.
When is next earnings date of PT Merck Tbk(ISX:MERK)?
The next earnings date of PT Merck Tbk(ISX:MERK) is .
Does PT Merck Tbk(ISX:MERK) pay dividends? If so, how much?
The Dividend Yield %  of PT Merck Tbk(ISX:MERK) is 8.91% (As of Today), Highest Dividend Payout Ratio of PT Merck Tbk(ISX:MERK) was 33.59. The lowest was 0.2. And the median was 0.8. The  Forward Dividend Yield % of PT Merck Tbk(ISX:MERK) is 8.91%. For more information regarding to dividend, please check our Dividend Page.
Press Release
| Subject | Date | |||
|---|---|---|---|---|
| No Press Release | ||||
Survey
We'd love to learn more about your experiences on GuruFocus.com and how we can improve!
Take Survey
Follow Us
Disclaimers